Little Rock, Arkansas
CNS clinical trials in Little Rock, AR
52 CNS studies are recruiting participants at sites in Little Rock as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Little Rock at a glance
- 52 studies are recruiting at a site in Little Rock.
- By phase: Phase 1 (1), Phase 1/2 (1), Phase 2 (14), Phase 3 (32), Phase 4 (4).
- By sponsor: industry (51), university, hospital or other (1).
- By research area: Schizophrenia (16), Depression (11), Migraine (6), Bipolar Disorder (5), Epilepsy (5), Parkinson's Disease (5), ADHD (4).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Little Rock
Basic details from each study's public record (the 30 most recently updated of 52). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Preferred Research Partners, Inc.
- Registry record
- NCT07592689 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- University of Arkansas for Medical Sciences
- Registry record
- NCT06748222 · updated
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- Phase 3
- Ages 10 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Pillar Clinical Research, LLC
- Registry record
- NCT06372964 · updated
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Neurocrine Biosciences
- Study site
- Neurocrine Clinical Site
- Registry record
- NCT06966401 · updated
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Draig Therapeutics Ltd
- Study site
- Draig Clinical Site
- Registry record
- NCT07610473 · updated
ALTO-100 in Bipolar Disorder With Depression (BD-D)
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT06656416 · updated
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Draig Therapeutics Ltd
- Study site
- Draig Clinical Site
- Registry record
- NCT07300969 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Little Rock, AR on ClinicalTrials.gov.
Schizophrenia studies recruiting in Little Rock
A Study to Evaluate the Effect of KarXT on Urological Safety
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Pillar Clinical Research- Little Rock
- Registry record
- NCT07221877 · updated
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Pillar Clinical Research, LLC
- Registry record
- NCT06229210 · updated
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
- Phase 2
- Ages 18 to 60
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT07680946 · updated
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Pillar Clinical Research- Little Rock
- Registry record
- NCT07686263 · updated
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- MapLight Therapeutics
- Registry record
- NCT07459647 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Little Rock, AR on ClinicalTrials.gov.
Bipolar disorder studies recruiting in Little Rock
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Pillar Clinical Research- Little Rock
- Registry record
- NCT06951711 · updated
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Pillar Clinical Research- Little Rock
- Registry record
- NCT07140913 · updated
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study sites
- Pillar Clinical Research- Little Rock · Woodland International Research Group
- Registry record
- NCT06929273 · updated
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Woodland International Research Group
- Registry record
- NCT06951698 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Little Rock, AR on ClinicalTrials.gov.
ADHD studies recruiting in Little Rock
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
- Phase 3
- Ages 6 to 11
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717879 · updated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717892 · updated
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Alkermes, Inc.
- Study site
- Alkermes Investigational Site
- Registry record
- NCT07755410 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Little Rock, AR on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Little Rock
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
- Phase 3
- Ages 45 to 75
- All sexes
- Sponsor
- BlueRock Therapeutics
- Study site
- University of Arkansas for Medical Sciences
- Registry record
- NCT06944522 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- University of Arkansas
- Registry record
- NCT06680830 · updated
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- Phase 2
- Ages 30 to 80
- All sexes
- Sponsor
- Appello Pharmaceuticals, Inc.
- Study site
- University of Arkansas for Medical Sciences (Site #208)
- Registry record
- NCT07432958 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Little Rock, AR on ClinicalTrials.gov.
Epilepsy studies recruiting in Little Rock
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- University of Arkansas for Medical Sciences
- Registry record
- NCT05667142 · updated
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Study site
- University of Arkansas for Medical Sciences
- Registry record
- NCT05135091 · updated
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
- Phase 3
- Ages 2 and older
- All sexes
- Sponsor
- Epygenix
- Study site
- Arkansas Children's Hospital
- Registry record
- NCT04462770 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Little Rock, AR on ClinicalTrials.gov.
Migraine studies recruiting in Little Rock
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Preferred Research Partners, Inc.
- Registry record
- NCT07816367 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Arkansas Clinical Research
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Arkansas Clinical Research
- Registry record
- NCT07674654 · updated
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- AbbVie
- Study site
- Preferred Research Partners /ID# 270389
- Registry record
- NCT06810505 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Little Rock, AR on ClinicalTrials.gov.
Ask about studies near Little Rock
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections